Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (2016 - 2025)

Adma Biologics (ADMA) has disclosed Shares Outstanding for 13 consecutive years, with $866302.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding fell 99.63% year-over-year to $866302.0, compared with a TTM value of $866302.0 through Dec 2025, down 99.63%, and an annual FY2025 reading of $866302.0, down 99.63% over the prior year.
  • Shares Outstanding was $866302.0 for Q4 2025 at Adma Biologics, down from $239.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $239.7 million in Q3 2025 and bottomed at $866302.0 in Q4 2025.
  • Average Shares Outstanding over 5 years is $197.8 million, with a median of $223.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding skyrocketed 86.66% in 2021, then crashed 99.63% in 2025.
  • Year by year, Shares Outstanding stood at $195.8 million in 2021, then increased by 13.28% to $221.8 million in 2022, then grew by 1.91% to $226.1 million in 2023, then rose by 4.67% to $236.6 million in 2024, then plummeted by 99.63% to $866302.0 in 2025.
  • Business Quant data shows Shares Outstanding for ADMA at $866302.0 in Q4 2025, $239.7 million in Q3 2025, and $239.4 million in Q2 2025.